[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 69 of about 69
55. Belgaumi AF: Hodgkin's lymphoma in the young child. Transfus Apher Sci; 2010 Apr;42(2):163-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in the young child.
  • Primarily a disease of adults, Hodgkin's lymphoma (HL) contributes significantly to pediatric malignant diseases, particularly in developing countries where the incidence is higher.
  • Patients with advanced disease have lower outcomes, which have improved with chemotherapy intensification.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Pediatrics

  • MedlinePlus Health Information. consumer health - Children's Health.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20100668.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Tsouchnikas I, Tsilipakou M, Daniilidis M, Kyriazis G, Pasadakis P, Parapanissiou E, Vargemezis V, Tsakiris D: Effect of iron loading on peripheral blood lymphocyte subsets and on circulating cytokine levels in iron-depleted hemodialysis patients receiving erythropoietin. Nephron Clin Pract; 2007;107(3):c97-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: High doses of iron are recommended intravenously in iron-depleted hemodialysis (HD) patients receiving recombinant erythropoietin (EPO).
  • The aim of this study was to evaluate the effect of iron load on peripheral blood lymphocytes subsets and on circulating cytokine levels in HD iron depleted patients, treated with EPO.
  • METHODS: We studied 19 stable adult HD patients, 12 males, with a mean age 59 +/- 11 years and mean HD duration 24 +/- 14 months.
  • The administered dose of iron was infused intravenously (1,000 mg iron sucrose) in 10 doses, during 10 consecutive HD sessions.
  • Patients were screened before the commencement of the HD session on two occasions, once prior to the first dose of iron and 2 days after the 10th dose.
  • CONCLUSION: Iron load in iron-deficient EPO-treated HD patients did not produce any changes in major lymphocyte subsets in peripheral blood, but it resulted in a significant increase of NKR+ T cells, a subpopulation important for local immune responses.
  • Iron load for a relatively short period improved anemia of HD patients and influenced the levels of the circulating IL-2, which may regulate factors affecting the survival of patients.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17890877.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cytokines; 11096-26-7 / Erythropoietin; E1UOL152H7 / Iron
  •  go-up   go-down


57. Cheema BS, Singh MA: Exercise training in patients receiving maintenance hemodialysis: a systematic review of clinical trials. Am J Nephrol; 2005 Jul-Aug;25(4):352-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exercise is not routinely advocated in patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis (HD), compared to best practice in other chronically diseased cohorts.
  • Lack of widespread awareness of the exercise in HD literature may be contributing to these shortcomings of clinical practice.
  • (1) to systematically review trials of exercise training involving adult HD patients;.
  • RESULTS: According to the 29 trials reviewed, HD patients can safely derive a myriad of health-related adaptations from engaging in appropriately structured exercise regimens involving aerobic and/or resistance training.
  • [MeSH-minor] Adaptation, Physiological. Adult. Clinical Trials as Topic. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16088076.001).
  • [ISSN] 0250-8095
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 48
  •  go-up   go-down


58. Rüffer JU, Ballova V, Glossmann J, Sieber M, Franklin J, Nogova L, Diehl V, Josting A, German Hodgkin Study Group: BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma; 2005 Nov;46(11):1561-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
  • Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results.
  • We retrospectively analysed patients with relapsed HD after initial radiation therapy alone to determine treatment outcome and prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Databases, Factual. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiation Dosage. Radiotherapy / methods. Remission Induction. Retrospective Studies. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236610.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol; CVPPABO protocol
  •  go-up   go-down


59. Marsenic O, Zhang L, Zuppa A, Barrett JS, Pfister M: Application of Individualized Bayesian Urea Kinetic Modeling to pediatric hemodialysis. ASAIO J; 2010 May-Jun;56(3):246-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incorporating urea rebound using equilibrated urea concentration (Ceq) after hemodialysis (HD) is essential for accurate assessment of HD efficiency.
  • The objective of this work is to assess the ability of an Individualized Bayesian Urea Kinetic Model (IBKM) for predicting Ceq in children receiving HD.
  • Developed based on adult HD data, the IBKM is a two-pool urea kinetic model that calculates Bayesian estimates of individual Ceq.
  • Blood urea nitrogen (BUN) samples from 30 HD sessions in 13 children (age 12-18 years) were taken at pre-HD, immediately post-HD, and 60 minutes post-HD (Ceq).
  • The IBKM and estimated population parameters from adult data were fitted to the observed data from children to predict individual Ceq using NONMEM VI software in comparison with observed Ceq (9.5 +/- 3.8 mmol/L), the average individual predicted Ceq was 9.4 +/- 3.8 mmol/L, with absolute individual prediction error of 6.2% +/- 4.4%.
  • This study suggests that the IBKM can be used in a pediatric HD setting and accurately predict Ceq in children using only pre-HD and immediately post-HD BUN.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168209.001).
  • [ISSN] 1538-943X
  • [Journal-full-title] ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • [ISO-abbreviation] ASAIO J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8W8T17847W / Urea
  •  go-up   go-down


60. Lokare A, Chaganti S, Lipkin G, Roberts C, Mahendra P: Posttransplant lymphoproliferative disorder followed by Hodgkins disease in a renal transplant recipient. Transplantation; 2008 Apr 27;85(8):1219-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant lymphoproliferative disorder followed by Hodgkins disease in a renal transplant recipient.
  • [MeSH-major] Hodgkin Disease / etiology. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / etiology
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431246.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


61. De Padua M, Kaul S, Sarin R, Kaul S, Das PK: Primary lymphoma of the breast: a clinicopathological study. Indian J Pathol Microbiol; 2007 Oct;50(4):722-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the breast: a clinicopathological study.
  • 3 cases of primary non Hodgkins lymphoma of the breast are described, seen over a period of 2 years among 199 cases of breast malignancies.
  • Application of immunohistochemistry greatly aids in differentiating lymphoma from anaplastic carcinoma, with which it can easily be confused.
  • Primary breast lymphoma is a rare disease with reported incidence of 0.04-0.53% of all breast malignancies in most series.
  • [MeSH-major] Breast Neoplasms / pathology. Hodgkin Disease / complications. Lymphoma / diagnosis. Lymphoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Carcinoma / diagnosis. Carcinoma / pathology. Cyclophosphamide. Diagnosis, Differential. Doxorubicin. Female. Humans. Middle Aged. Prednisolone. Vincristine

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306536.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


62. Nguyen HP, Metzger S, Holzmann C, Koczan D, Thiesen HJ, von Hörsten S, Riess O, Bonin M: Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics Clin Appl; 2008 Dec;2(12):1638-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease.
  • Polyglutamine-induced changes in gene expression have been demonstrated by using several mouse models of Huntington's disease (HD), which express extreme numbers of CAG repeats.
  • We have recently developed a transgenic rat model of HD carrying a truncated huntingtin fragment with 51 CAG repeats, which is in the range seen in adult HD patients.
  • A detailed analysis of canonical pathways revealed that at 3 months of age genes in calcium signaling and synaptic long term potentation pathways were altered, while at 12 months of age, additionally, expression level of many genes implicated in Huntington's disease signaling, were changed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21136814.001).
  • [ISSN] 1862-8346
  • [Journal-full-title] Proteomics. Clinical applications
  • [ISO-abbreviation] Proteomics Clin Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Al-Mulhim FA: Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma. Saudi Med J; 2005 Jan;26(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma.
  • OBJECTIVE: Detection of the residual bone marrow (BM) involvement is essential in treatment of patients with non-Hodgkin's lymphoma (NHL).
  • This study was conducted to determine the advantage of femoral marrow MRI as a non-invasive technique over bilateral iliac crest BM biopsies in detecting BM infiltration before treatment and residual disease after completion of treatment.
  • [MeSH-major] Bone Marrow / pathology. Femur / pathology. Lymphoma, Non-Hodgkin / pathology. Magnetic Resonance Imaging. Pelvis / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Saudi Med J. 2005 May;26(5):898
  • (PMID = 15756349.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


6
Advertisement
4. Harris RE, Beebe-Donk J, Doss H, Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep; 2005 Apr;13(4):559-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial epidemiologic studies of malignant melanoma, Hodgkin's disease, and adult leukemia also found that NSAIDs are protective.
  • [MeSH-minor] Animals. Case-Control Studies. Cohort Studies. Cyclooxygenase 1. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Disease Models, Animal. Female. Humans. Male. Membrane Proteins. Models, Biological. Risk. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Aug;174(2):787-8 [16006977.001]
  • (PMID = 15756426.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; R16CO5Y76E / Aspirin; WK2XYI10QM / Ibuprofen
  • [Number-of-references] 264
  •  go-up   go-down


65. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F: Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets; 2010 Dec;9(6):791-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
  • Huntington's disease (HD) is an adult onset neurodegenerative disease caused by a polyglutamine expansion in the huntingtin protein.
  • Recent work has shown that perturbation of kynurenine pathway (KP) metabolism is a hallmark of HD pathology, and that changes in brain levels of KP metabolites may play a causative role in this disease.
  • Recent studies with HD patient samples and in HD model systems have supported the idea that a shift away from the synthesis of KYNA and towards the formation of 3-HK and QUIN may trigger the neuropathological features observed in HD.
  • This intervention ameliorates disease-relevant phenotypes in HD models.
  • Here we review the work implicating the KP in HD pathology and discuss the potential of KMO as a therapeutic target for this disorder.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942784.001).
  • [ISSN] 1996-3181
  • [Journal-full-title] CNS & neurological disorders drug targets
  • [ISO-abbreviation] CNS Neurol Disord Drug Targets
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS057715; United Kingdom / Medical Research Council / / G0700090; United States / NINDS NIH HHS / NS / NS057715
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 343-65-7 / Kynurenine; EC 1.14.13.9 / Kynurenine 3-Monooxygenase
  •  go-up   go-down


66. Hodgins M, Millar M, Barry MM: "...it's all the same no matter how much fruit or vegetables or fresh air we get": traveller women's perceptions of illness causation and health inequalities. Soc Sci Med; 2006 Apr;62(8):1978-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-one Traveller women were recruited to the focus groups through community projects or adult education initiatives.
  • Further, they broadly rejected behavioural explanations of the heart disease described in the vignette.
  • [MeSH-major] Disease / etiology. Ethnic Groups. Fruit. Health Status. Population Groups. Vegetables
  • [MeSH-minor] Adult. Culture. Female. Focus Groups. Health Services Accessibility. Humans. Ireland. Life Style. Social Identification

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213642.001).
  • [ISSN] 0277-9536
  • [Journal-full-title] Social science & medicine (1982)
  • [ISO-abbreviation] Soc Sci Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Musacchio JG, Carvalho Mda G, Morais JC, Silva NH, Scheliga A, Romano S, Spector N: Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease. Sao Paulo Med J; 2006 May 4;124(3):154-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease.
  • CONTEXT AND OBJECTIVE: Free circulating Epstein-Barr virus (EBV) DNA is often present in the plasma of Hodgkins disease patients.
  • DESIGN AND SETTING: Prospective study in two public tertiary institutions: Hematology Service, Universidade Federal do Rio de Janeiro, and Oncology Service, Instituto Nacional do Câncer, Rio de Janeiro.
  • METHODS: A cohort of 30 patients with newly diagnosed Hodgkins disease was studied.
  • The control group consisted of 13 healthy adult volunteers.
  • Advanced disease was present in 19 patients, and six were HIV-positive.
  • EBV DNA prevalence was higher in HIV-positive patients (100% versus 29%, p = 0.0007) and those with advanced disease (63% versus 9%, p = 0.006).
  • Among HIV-negative patients alone, EBV DNA prevalence remained higher in those with advanced disease.
  • CONCLUSION: EBV DNA was present in 91% of patients with EBV-associated Hodgkins disease, and in all patients with HIV-associated Hodgkins disease.
  • EBV DNA prevalence was higher in patients with advanced disease, irrespective of HIV status.
  • [MeSH-major] DNA, Viral / blood. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Biomarkers / blood. Case-Control Studies. Chi-Square Distribution. Child. Female. HIV Infections / blood. HIV Infections / virology. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies. Viral Load. Viral Matrix Proteins / blood

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119693.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


68. Hobbie WL, Ginsberg JP, Ogle SK, Carlson CA, Meadows AT: Fertility in males treated for Hodgkins disease with COPP/ABV hybrid. Pediatr Blood Cancer; 2005 Feb;44(2):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility in males treated for Hodgkins disease with COPP/ABV hybrid.
  • More than 80% of those diagnosed with Hodgkins disease (HD) will survive long-term.
  • For the past decade, a modified hybrid consisting of cyclophosphamide (2.4-3.6g/m(2)), vincristine, procarbazine, and prednisone (COPP) together with adriamycin, bleomycin, and vinblastine (ABV) has been used to treat patients with HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility / drug effects. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Child. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Humans. Male. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15390272.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00240
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; VBA protocol
  •  go-up   go-down


69. Slovacek L, Slovackova B, Jebavy L, Macingova Z: Psychosocial, health and demographic characteristics of quality of life among patients with acute myeloid leukemia and malignant lymphoma who underwent autologous hematopoietic stem cell transplantation. Sao Paulo Med J; 2007 Nov 1;125(6):359-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychosocial, health and demographic characteristics of quality of life among patients with acute myeloid leukemia and malignant lymphoma who underwent autologous hematopoietic stem cell transplantation.
  • METHODS: The Czech version of the international generic European Quality-of-Life questionnaire (EQ-5D) was applied to evaluate QOL among patients with acute myeloid leukemia (AML) and malignant Hodgkins and non-Hodgkins lymphoma (ML).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / psychology. Hodgkin Disease / surgery. Leukemia, Myeloid, Acute / therapy. Lymphoma, Non-Hodgkin / surgery. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Analysis of Variance. Czech Republic. Educational Status. Female. Health Surveys. Humans. Male. Middle Aged. Retrospective Studies. Smoking / adverse effects. Surveys and Questionnaires. Young Adult






Advertisement